

No. 31026/60/2020-Policy
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

Kartavya Bhawan 2, New Delhi
Dated 30th October, 2026

CORRIGENDUM

Subject: Modifications in Appendix B of the operational guidelines pertaining to Group C (MSME) applicants under the Production Linked Incentive (PLI) Scheme for Pharmaceuticals –reg.

Department of Pharmaceuticals issued operational guidelines of the PLI Scheme for Pharmaceuticals on 01.6.2021, as revised on 30.6.2021, 13.8.2021, 20.10.2022, 17.3.2023, 20.10.2023 and 11.3.2024.

2. In continuation to the above, following amendment in the Appendix B of the guidelines of the PLI Scheme for Pharmaceuticals is hereby notified with the approval of the competent authority:

Threshold criteria for eligibility of incentive

Group of Participants	Existing schedule for minimum cumulative investment to be achieved by end of corresponding FY per participant (in crore ₹)	Revised schedule for minimum cumulative investment to be achieved by end of corresponding FY per participant (in crore ₹)
Group C (MSME)	FY2021-22: 20% of CI FY2022-23: 40% of CI FY2023-24: 60% of CI FY2024-25: 80% of CI FY2025-26: 100% of CI	FY2022-23: 20% of CI FY2023-24: 40% of CI FY2024-25: 60% of CI FY2025-26: 80% of CI FY2026-27: 100% of CI

3. Therefore, under this addendum, the minimum investment required to be achieved by an applicant would be as per the following revised investment schedule:

- FY2020–21 to FY2022–23: 20% of committed cumulative investment
- By end of FY2023–24: 40% of committed cumulative investment
- By end of FY2024–25: 60% of committed cumulative investment
- By end of FY2025–26: 80% of committed cumulative investment
- By end of FY2026–27: 100% of committed cumulative investment

4. Those applicants who may be eligible to claim incentive as per the revised investment schedule criteria, need to apply and submit fresh claim applications for incentive disbursement for the previous performance years and the same would be examined in accordance with the scheme guidelines, Standard Operating Procedure and applicable corrigendums/addendums.


5. Except for the change as specified in Para 2 above applicable only for Group C (MSME) applicants, all other clauses in the PLI Scheme for Pharmaceuticals operational guidelines dated 1.6.2021 and subsequent corrigendums/addendums, shall remain the same and continue to be applicable as earlier.

6. For the sake of clarity, it is additionally clarified that there shall be no change in existing eligibility criteria requiring achievement of minimum year-on-year (YoY) percentage growth in sales and it shall continue to be applicable, as specified in Appendix B of the operational guidelines dated 1.6.2021.

7. Further, the performance years for calculating incremental sales, for the purpose of disbursement of incentive, shall remain unchanged and will continue to be determined as prescribed under the scheme guidelines dated 1.6.2021 (viz. the performance years shall continue to be from FY 2022–23 to FY 2027–28).

Effect of the corrigendum: Group-C (MSME) beneficiaries under the Production Linked Incentive (PLI) Scheme for Pharmaceuticals shall be provided an additional year each, for meeting the stipulated year wise minimum cumulative investment, without any other change in the scheme guidelines.

8. This issues with the approval of competent authority.



30/10/2026
(Suhas Bhuyan)

Under Secretary to the Government of India
Tel.: 011-24013612

Email: us-pharmaschemes@pharma-dept.gov.in

To

1. General Manager, Small Industries Development Bank of India, Atma Ram House, 1 Tolstoy Marg, New Delhi-110 001
2. Head of Group, Department of Pharmaceuticals Informatics Division, National Informatics Centre — with a request to upload this notice on the website of the Department of Pharmaceuticals